# Study of SHR-1210 Combined With Apatinib in the Treatment of Sarcoma

> **NCT04126993** · PHASE2 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 80 (estimated)

## Conditions studied

- Sarcoma

## Interventions

- **DRUG:** Camrelizumab,
- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT04126993
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-01
- **Primary completion:** 2019-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2019-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04126993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04126993, "Study of SHR-1210 Combined With Apatinib in the Treatment of Sarcoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04126993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*